# Extracted Results from 100380191.pdf


*** PROMPT:Use use the report data to identify the company name and stock market tickr.  Also list the both current and target share price.
Okay, I have analyzed the financial forecast report. Here's the information you requested:

*   **Company Name:** Novo Nordisk
*   **Stock Market Ticker:** NOVOB DC (Bloomberg), NOVOb.CO (Reuters) (Page 1)
*   **Current Share Price:** DKK 958.0 (Page 1)
*   **Target Share Price:** DKK 1,150 (Page 1)


*** PROMPT:List the actual sales revenue for each historic year reported, plus revenue for all years for which there are estimates.
Ok, here's the sales revenue extracted from the document, along with the section and page where the data was found:

**Section: Company Overview, Page 20**

*   **2018A:** DKK 111,831m
*   **2019A:** DKK 122,021m
*   **2020A:** DKK 126,946m
*   **2021A:** DKK 140,800m
*   **2022A:** DKK 176,954m
*   **2023E:** DKK 199,753m
*   **2024E:** DKK 226,936m
*   **2025E:** DKK 257,572m

*** PROMPT:List the actual Earnings Per Share (EPS) for each historic year reported, plus EPS for all years for which there are estimates.
Here's the requested information on Earnings Per Share (EPS), extracted from the financial forecast report:

*   **Section:** DKKm section, Sales description table. Page 1
    *   **2020:** DKK 18.1
    *   **2021:** DKK 20.7
    *   **2022:** DKK 24.4
    *   **2023E:** DKK 30.3
    *   **2024E:** DKK 33.6
    *   **2025E:** DKK 39.8

*** PROMPT:List the actual Earnings Before Interest and Taxes (EBIT) for each historic year reported, plus EBIT for all years for which there are estimates.
Certainly! Here's the EBIT information from the report you provided:

**Section:** First page, table.

*   **2020:** DKKm 54,126
*   **2021:** DKKm 58,644
*   **2022:** DKKm 74,809
*   **2023e:** DKKm 83,528
*   **2024e:** DKKm 94,371
*   **2025e:** DKKm 109,743

The EBIT values are expressed in DKKm (Danish Krone in millions).

*** PROMPT:List the actual Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) for each historic year reported, plus EBITDA for all years for which there are estimates.
Okay, here are the actual and estimated Earnings Before Interest, Taxes, Depreciation, and Amortisation (EBITDA) figures from the report, along with the section and page where the information was found:

**Section: Company Overview, Page 20**

*   **2018:** DKKm 50,057
*   **2019:** DKKm 56,941
*   **2020:** DKKm 59,863
*   **2021:** DKKm 64,638
*   **2022:** DKKm 82,122
*   **2023e:** DKKm 90,620
*   **2024e:** DKKm 102,211
*   **2025e:** DKKm 118,425

*** PROMPT:List the actual Earnings Before Interest, Taxes, Depreciation, Amortisation, and Restructuring or Rent (EBITDAR) for each historic year reported, plus EBITDAR for all years for which there are estimates.
Here's the EBITDAR data extracted from the financial forecast report you provided:

Based on information from page 2 and 13:

*   **2020:** Data not available.
*   **2021:** Data not available.
*   **2023e:** Data not available.
*   **2024e:** Data not available.
*   **2025e:** Data not available.

*** PROMPT:List the actual Earnings Before Interest and Taxes Margin (EBIT Margin) for each historic year reported, plus EBIT Margin for all years for which there are estimates.
Okay, here's the information on Earnings Before Interest and Taxes (EBIT) Margin for Novo Nordisk, based on the provided financial forecast report:

*   **Section:** Table at bottom of page 1
*   **Scaling:** DKKm (Danish Krone millions)

Here are the EBIT Margin values:

*   **2020:** 42.6%
*   **2021:** 41.7%
*   **2022:** 42.3%
*   **2023e:** 41.8%
*   **2024e:** 41.6%
*   **2025e:** 42.6%

*** PROMPT:List the actual Current Assets for each historic year reported, plus Current Assets for all years for which there are estimates.
Ok, I can help you with that.

Based on the financial forecast report you provided, here's the Current Assets information:

*   **2020:** Data not available
*   **2021:** Data not available
*   **2022:** Data not available
*   **2023e:** Data not available
*   **2024e:** Data not available
*   **2025e:** Data not available

I was not able to find the actual or estimated Current Assets in the report.

**Location:** Not available


*** PROMPT:List the actual Current Liabilities for each historic year reported, plus Current Liabilities for all years for which there are estimates.
Here are the Current Liabilities for the years requested.

*   **2018:** DKK 54,164m (Section: Company Overview)
*   **2019:** DKK 58,983m (Section: Company Overview)
*   **2020:** DKK 70,273m (Section: Company Overview)
*   **2021:** DKK 99,516m (Section: Company Overview)
*   **2022:** DKK 120,940m (Section: Company Overview)
*   **2023e:** DKK 136,333m (Section: Company Overview)
*   **2024e:** DKK 154,687m (Section: Company Overview)
*   **2025e:** DKK 175,371m (Section: Company Overview)

*** PROMPT:List the actual Total Liabilities for each historic year reported, plus Total Liabilities for all years for which there are estimates.
Here are the Total Liabilities for the years requested, based on the provided document:

**Section:** Company overview, page 20

*   **2018:** 110,769 DKKm
*   **2019:** 125,612 DKKm
*   **2020:** 144,922 DKKm
*   **2021:** 194,508 DKKm
*   **2022:** 241,257 DKKm
*   **2023e:** 282,071 DKKm
*   **2024e:** 323,603 DKKm
*   **2025e:** 373,725 DKKm

*** PROMPT:Does the report indicate this stock is a recommendation to buy, sell or hold?  If so, what is the target price and the rationale for the recommendation?
Based on the provided report:

*   The stock is recommended as **HOLD/MARKET PERFORM** (Page 1, "Novo Nordisk" Section).
*   The target price is **DKK1,150** (Page 1, "Novo Nordisk" Section).

The rationale for the recommendation is not explicitly stated in the extracted text, it only indicates that the focus is turning to weekly Wegovy prescriptions data.&#x20;

